13734-28-6 Boc-Lys-OH, tseem hu ua N-alpha-tert-butoxycarbonyl-L-lysine, yog biochemical reagent uas tuaj yeem siv los ua lub tsev thaiv hauv ntau yam kev tshawb fawb txog lub neej.
Tshwj xeeb, 13734-28-6 Boc-Lys-OH koom nrog hauv kev sib txuas ntawm thymic peptides xws li β4, βg, thiab β6 fragments.Nws txhim kho E-rosette tsim muaj peev xwm thiab ua lub luag haujlwm hauv lupus nephritis qauv.Tsis tas li ntawd, Boc-Lys-OH yog siv nyob rau hauv lub synthesis ntawm Boc-Lyz-OCH3 thiab ua hauj lwm raws li ib tug ntau lawm reagent rau peptide-raws li thrombin inhibitors.
13734-28-6 Boc-Lys-OH yog ib qho ntawm Tirzepatide intermediates.
Tirzepatide yog ib qho tshiab glucagon-zoo li peptide-1 receptor (GLP-1) thiab qabzib-nyob ntawm insulinotropic polypeptide (GIP) dual receptor agonist, ua haujlwm ib zaug ib lim tiam.GLP-1 thiab GIP yog ob qho tib si enteroglucagon, peptides secreted los ntawm mucosa ntawm txoj hnyuv. kab mob ntawm tib neeg lub cev, thiab yav dhau los tuaj yeem khi rau cov receptor ntawm pancreatic islet hlwb thiab txhawb kev tso tawm ntawm insulin, yog li tsim cov piam thaj txo qis, thiab nws tseem ua rau lub plab zom mov thiab txo qis qab los noj mov, yog li tswj lub cev hnyav;thaum kawg muaj cov haujlwm ntawm inhibiting gastric acid, txhawb kev tso tawm ntawm insulin, thiab inhibiting gastric motility thiab khoob, uas tuaj yeem ntxiv GLP-1.Cov qub tuaj yeem khi rau cov receptors ntawm pancreatic islet hlwb thiab txhawb kev tsim cov tshuaj insulin, yog li tsim cov nyhuv hypoglycemic, nrog rau ncua kev ua pa ntawm plab thiab txo qis qab los noj mov, yog li tswj lub cev hnyav;thaum kawg muaj cov haujlwm ntawm inhibiting gastric acid thiab pepsin secretion, stimulating insulin tso tawm, inhibiting gastric peristalsis thiab khoob, thiab tuaj yeem ntxiv lub luag haujlwm ntawm GLP-1 agonist.